PROTAC ERα Degrader-5

• CAS Number:

  2158322-33-7

• UNSPSC Description:

  PROTAC ERα Degrader-5 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. PROTAC ERα Degrader-5 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab)[1].

• Target Antigen:

  Estrogen Receptor/ERR; PROTAC-Linker Conjugates for PAC

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;PROTAC;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/PAC.html

• Purity:

  98.96

• Solubility:

  DMSO : 70 mg/mL (ultrasonic)

• Smiles:

  CN(C(COCCOCCNC(C1=CC=C(C(N2[C@@H](C)[C@H](NC([C@H](C)NC)=O)C(N(CC3=C(OC)C=CC4=C3C=CC=C4)C5=C2C=C(C#N)C=C5)=O)=O)C=C1)=O)=O)CCOC(C=C6)=CC=C6/C(C7=CC=C(OCC(C=C8)=CC=C8NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN9C(C=CC9=O)=O)=O)=O)=O)C=C7)=C(C%10=CC=CC=C%10)/CC

• Molecular Weight:

  1674.93

• References & Citations:

  [1]Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported